In this era of accelerating information, it is more critical than ever to be clear and engaging in medical publications – and that increasingly involves the skill of scientific storytelling, to ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring for people living with heart failure. Called Digitiva, it combines Eko ...

Investment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and ...

Onsite at the Boehringer Ingelheim R&D centre in Biberach, Germany, the conversation also circled around Boehringer’s One Medicine Project, originally announced in March 2022, but the central focus ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI). The study used ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

In an age of greenwashing, where ESG (environmental, social, governance) increasingly feels like a corporate buzzword, how do you find the companies that are not only talking the talk, but walking ...

The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down. Emerson has ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that. The clinical ...